1. Introduction {#sec1}
===============

An emerging coronavirus, currently known as "Severe Acute Respiratory Syndrome coronavirus type 2" (SARS-CoV-2) and previously termed as "2019 novel coronavirus" (2019-nCoV), has spread out from its first reported epicenter and quickly become a pandemic [@b1], [@b2].

SARS-CoV-2 causes a generally mild, but sometimes severe and even life-threatening infection, known as "coronavirus disease" (COVID-19). Currently, there exist no effective vaccines or drugs that can effectively prevent or treat COVID-19 patients. As such, global public authorities have so far relied upon behavioral, non pharmaceutical interventions (NPIs), such as use of masks, social distancing, self-isolation, quarantine and even lock-down of entire territories and communities, to contain or, at least, mitigate the burden of the ongoing pandemic [@b3], [@b4], [@b5]. Despite the unprecedented nature of some of these measures, western countries have found it difficult to fully suppress/eradicate the outbreak and have preferred to mitigate it, deciding to opt for a short-period of NPIs, which will be followed by gradual reopening the economy and return to a new normal. Resumption of daily working and social activities is expected to cause further outbreak waves, due to the re-increasing of contact rates.

In [@b6], Sajadi et al. provided the evidence that COVID-19 could perhaps prevail at low levels and begin to rise again in late fall and winter in temperate regions in the upcoming year. Since COVID-19 symptoms are aspecific and may resemble a common cold, if it should come back with a seasonal pattern and coincide with the influenza season, this would be particularly challenging. From a clinical standpoint, it would be difficult to distinguish between the two infectious agents, with the definition of COVID-19 cases rather problematic. Moreover, diagnostic tests as well as human resources are limited. Furthermore, currently commercially available rapid diagnostic tests are characterized by a good specificity but have a limited sensitivity, as such not enabling a quick and reliable diagnosis of COVID-19. Altogether, this would significantly impact downstream public health efforts to properly identify COVID-19 cases and contain the outbreak, overwhelming and straining the healthcare systems, particularly in resource-limited contexts, and would increase the likelihood of nosocomial transmission.

When the "Severe Acute Respiratory Syndrome" (SARS) outbreak caused by the coronavirus SARS-CoV-1 occurred in mainland China in 2002, the World Health Organization (WHO) has recommended to increase influenza vaccination, considering that the actual coverage rate is still sub-optimal and below the threshold. In particular, the WHO recommended a campaign targeting high-risk groups, such as healthcare workers, the elderly and disabled people, to be able to differentiate more quickly between the two infections and to be more effective in counteracting the outbreak [@b7], [@b8], [@b9].

A similar strategy would be valuable also for COVID-19. To test such a hypothesis, we devised a mathematical model incorporating the treatment of people complaining of ILI symptoms, potentially at risk of contracting COVID-19 or other emerging/re-emerging respiratory infectious agents during their admission at the health-care setting, where the competition of the detection resources between the COVID-19 infected population and individuals with ILI symptoms is considered. The main purpose of this study is using the model to assess the effect of mass influenza vaccination and public health interventions on the spread of COVID-19 in the case of a coincidence of the outbreak with the influenza season.

2. Methodology {#sec2}
==============

2.1. Data {#sec2.1}
---------

We obtained the data of COVID-19 cases in China from January 23rd to March 29th 2020 from the National Health Commission of the People's Republic of China [@b10]. The data information includes the cumulative number of confirmed cases, the cumulative number of death cases, the cumulative number of cured cases, and the cumulative number of suspected cases, shown in [Fig. 1](#fig1){ref-type="fig"}. It should be mentioned that the number of suspected cases includes the number of quarantined COVID-19 exposed cases, the number of quarantined COVID-19 infected cases but not confirmed yet, and the number of quarantined individuals with clinical fever symptoms who are susceptible to COVID-19.

Fig. 1The data of COVID-19 in China from January to March 2020. (A) The cumulative number of confirmed cases; (B) The cumulative number of death cases; (C) The cumulative number of cured cases; (D) The cumulative number of suspected cases.

2.2. Model {#sec2.2}
----------

Based on the epidemical progression of COVID-19 and the intervention measures, we extended the classical SEIR model by including social distancing measures and including "cross-infected" individuals, those who are having clinical fever symptoms and are considered as COVID-19 suspected (and thus quarantined) due to their exposure to COVID-19 infected individuals. The transmission diagram is shown in [Fig. 2](#fig2){ref-type="fig"}. In the model, we divide the total population $N$ into ten compartments: susceptible ($S$), exposed ($E$), symptomatic infected ($I$), asymptomatic infected ($A$), quarantined susceptible ($S_{q}$), quarantined susceptible with fever symptoms ($S_{f}$), quarantined exposed ($E_{q}$), quarantined infected ($I_{q}$), confirmed and hospitalized ($H$), and recovered ($R$).

With the implementation of contact tracing, a proportion of $q$ of individuals exposed to the virus is quarantined. Let the transmission probability be $\beta$ and the contact rate be $c$, then the quarantined individuals can move to compartment $E_{q}$ (or $S_{q}$) at a rate of $\beta cq$ (or $\left( 1 - \beta \right)cq$) if they are effectively infected (or not effectively infected). While the other proportion, $1 - q$, missed from the contact tracing, will move to the exposed compartment $E$ at a rate of $\beta c\left( 1 - q \right)$ once effectively infected or stay in the susceptible compartment $S$ otherwise.Fig. 2Diagram of the model adopted in the study for illustrating the COVID-19 infection dynamics. Interventions including intensive contact tracing followed by quarantine and isolation are indicated. The total suspected cases consisting of quarantined susceptible with clinical fever symptoms ($S_{f}$), quarantined exposed ($E_{q}$), and quarantined infected ($I_{q}$).

Note that, due to clinical fever or illness-like symptoms, susceptible individuals may also be quarantined and move to the compartment $S_{f}$ at a transition rate of $m$, and they can be infected by the quarantined infected individuals at a rate of $\beta_{f}c_{f}$. Based on the above assumptions and previous studies [@b5], [@b11], [@b12], the transmission dynamics is governed by the following model: $$\left\{ \begin{array}{lll}
S^{\prime} & = & {- \frac{\left( {\beta c\left( t \right) + c\left( t \right)q\left( t \right)\left( 1 - \beta \right)} \right)SI}{N} - \frac{\beta_{A}c\left( t \right)SA}{N} - m\left( t \right)S + \lambda S_{q} + \lambda_{f}S_{f},} \\
E^{\prime} & = & {\frac{\beta c\left( t \right)\left( 1 - q\left( t \right) \right)SI}{N} + \frac{\beta_{A}c\left( t \right)SA}{N} - \sigma E,} \\
I^{\prime} & = & {\sigma\rho E - F_{1}\left( {I,I_{q},S_{f}} \right) - \alpha\left( t \right)I,} \\
A^{\prime} & = & {\sigma\left( 1 - \rho \right)E - \gamma_{A}A,} \\
S_{q}^{\prime} & = & {\frac{c\left( t \right)q\left( t \right)\left( 1 - \beta \right)SI}{N} - \lambda S_{q},} \\
S_{f}^{\prime} & = & {m\left( t \right)S - \beta_{f}c_{f}S_{f}I_{q} - \lambda_{f}S_{f},} \\
E_{q}^{\prime} & = & {\frac{\beta c\left( t \right)q\left( t \right)SI}{N} + \beta_{f}c_{f}S_{f}I_{q} - \sigma_{q}E_{q},} \\
I_{q}^{\prime} & = & {\sigma_{q}E_{q} - F_{2}\left( {I,I_{q},S_{f}} \right) - \alpha\left( t \right)I_{q},} \\
H^{\prime} & = & {F_{1}\left( {I,I_{q},S_{f}} \right) + F_{2}\left( {I,I_{q},S_{f}} \right) - \alpha\left( t \right)H - \gamma_{H}\left( t \right)H,} \\
R^{\prime} & = & {\gamma_{A}A + \gamma_{H}\left( t \right)H.} \\
\end{array} \right)$$The detailed definitions of all the parameters and variables are listed in [Table 1](#tbl1){ref-type="table"}.

A significant difference between the COVID-19 transmission dynamics model in our previous studies [@b11], [@b12], [@b14] and the current study is the introduction of two saturated functions $$F_{1}\left( {I,I_{q},S_{f}} \right) = \frac{\delta_{I}I}{1 + \omega\left( t \right)\left( {I + I_{q} + S_{f}} \right)}$$and $$F_{2}\left( {I,I_{q},S_{f}} \right) = \frac{\delta_{q}I_{q}}{1 + \omega\left( t \right)\left( {I + I_{q} + S_{f}} \right)},$$to describe the impact of "cross-infection" on the diagnose rate of the infected class ($I$) and the detection rate of the quarantined infected class ($I_{q}$) with limited testing capacity, respectively. $\delta_{I}$ and $\delta_{q}$ are the fastest diagnose rate of infected individuals and quarantined infected individuals, respectively, that the medical resources permit, $\frac{1}{\omega\left( t \right)}$ is the maximum number of individuals who can be tested per unit time (day) (limited by the maximum testing kits and staff to administrate the test) with $\lim_{I\rightarrow\infty}F_{1}\left( {I,I_{q},S_{f}} \right) = \frac{\delta_{I}}{\omega\left( t \right)}$ and $\lim_{I_{q}\rightarrow\infty}F_{2}\left( {I,I_{q},S_{f}} \right) = \frac{\delta_{q}}{\omega\left( t \right)}$. In other word, $\frac{1}{\omega\left( t \right)}$ measures the testing capacity per day. Here, we set the daily capacity as an increasing function of time $t$ because of the increasing production of detection kits and the improvement of detection techniques. The function of $\frac{1}{\omega\left( t \right)}$ is of the following form: $$\frac{1}{\omega\left( t \right)} = \left( {\frac{1}{\omega_{0}} - \frac{1}{\omega_{b}}} \right)e^{- r_{\omega}t} + \frac{1}{\omega_{b}},$$where $\frac{1}{\omega_{0}}$ is the total number of available detection kits at the initial time (i.e. January $23^{rd}$) with $\omega\left( 0 \right) = \omega_{0}$, $\frac{1}{\omega_{b}}$ is the maximum number of available tests permitted with $\lim_{t\rightarrow\infty}\omega\left( t \right) = \omega_{b} > \omega_{0}$, and $r_{\omega}$ is the exponential increasing rate.Table 1Parameter estimates for the COVID-19 epidemics in China.ParameterDefinitionValueSource$c\left( t \right)$$c_{0}$Contact rate at the initial time14.781[@b11]$c_{b}$Minimum contact rate with control strategies2.0Estimated$r_{c}$Exponential decreasing rate of contact rate0.1Estimated$\beta$Transmission probability from $I$ to $S$ per contact0.18Estimated$q\left( t \right)$$q_{0}$Quarantined rate at the initial time$1.0 \times 10^{- 4}$[@b12]$q_{b}$Maximum quarantined rate with control strategies0.9Estimated$r_{q}$Exponential increasing rate of quarantined rate0.1Estimated$\beta_{A}$Transmission probability from $A$ to $S$ per contact0.01Estimated$m\left( t \right)$$m_{0}$Quarantined rate of susceptible population with fever symptoms at the initial time$2.0848 \times 10^{- 4}$Estimated$m_{b}$Minimal quarantined rate of susceptibles with fever symptoms$5.0001 \times 10^{- 7}$Estimated$r_{m}$Exponential decreasing rate of quarantined rate0.0567Estimated$\lambda$Releasing rate of quarantined susceptibles$\left. 1\slash 14 \right.$[@b11]$\lambda_{f}$Releasing rate of quarantined susceptibles with fever symptoms0.1Estimated$\rho$Ratio of symptomatic infection0.5Estimated$\sigma$Transition rate of exposed individuals to the infected class$\left. 1\slash 5 \right.$[@b13]$\delta_{I}$Fast diagnose rate of infected individuals0.5Estimated$\left. 1\slash\omega\left( t \right) \right.$$\left. 1\slash\omega_{0} \right.$Initial number of detection kits per day2000Estimated$\left. 1\slash\omega_{b} \right.$Maximal number of detection kits per day$1.0 \times 10^{- 5}$Estimated$r_{\omega}$Exponential increasing rate of the number of detection kits0.885Estimated$\gamma_{A}$Recovery rate of asymptotic infected individuals0.13978[@b11]$\alpha\left( t \right)$$\alpha_{0}$Disease-induced death rate at the initial time0.012Estimated$\alpha_{b}$Minimal disease-induced death rate with treatment0.0012Estimated$r_{\alpha}$Exponential increasing rate of disease-induced death rate0.1129Estimated$\beta_{f}$Transmission rate from $I_{q}$ to $S_{f}$$3.0 \times 10^{- 6}$Estimated$c_{f}$Contact rate of suspected cases2.0Estimated$\sigma_{q}$Transition rate of quarantined exposed individuals to the quarantined infected class0.2Estimated$\delta_{q}$Fast diagnose rate of quarantined individuals1.0Estimated$\gamma_{H}\left( t \right)$$\gamma_{H0}$Recovery rate of confirmed individuals at the initial time0.001Estimated$\gamma_{Hb}$Maximal recovery rate of confirmed individuals with treatment0.15Estimated$r_{\gamma}$Exponential increasing rate of recovery rate0.0123EstimatedVariableDefinitionInitial valueSource$S$Susceptible population$1.5 \times 10^{7}$Estimated$E$Exposed population8216Estimated$I$Infected symptomatic population1000Estimated$A$Infected asymptomatic population1000Estimated$S_{q}$Quarantined susceptible population7347Data$S_{f}$Quarantined susceptible population with fever symptoms499.9975Estimated$E_{q}$Quarantined exposed population100.0003Estimated$I_{q}$Quarantined infected population250.0005Estimated$H$Confirmed and hospitalized population771Data$R$Recovered population34Data

The saturation functions $F_{1}\left( {I,I_{q},S_{f}} \right)$ and $F_{2}\left( {I,I_{q},S_{f}} \right)$ are decreasing functions with respect to $S_{f}$. This is because the quarantined COVID-19 susceptible individuals with fever symptoms belong to the COVID-19 suspected population, and will be tested to confirm if they are COVID-19 positive or not. These individuals will consume the detection kits and require staff time, resulting in a slower detection rate of the COVID-19 infected cases.

Similarly to the previous studies [@b12], [@b14], as a result of the improvement of medical treatment and the implementation of a series of strict control interventions adopted by the Chinese government since January 23rd, we assume that the contact rate $c$, the quarantine rate $q$, the quarantine rate of susceptible population with clinical fever symptoms $m$, disease-induced death rate $\alpha$, and recovery rate of confirmed individuals $\gamma_{H}$ are time-dependent functions. In more details, the contact rate $c\left( t \right)$ is a decreasing function with respect to time $t$, which is given by $$c\left( t \right) = \left( {c_{0} - c_{b}} \right)e^{- r_{c}t} + c_{b},$$where $c_{0}$ is the contact rate at the initial time with $c\left( 0 \right) = c_{0}$, $c_{b}$ is the minimum contact rate under control measures and self-isolation with $\lim_{t\rightarrow\infty}c\left( t \right) = c_{b} < c_{0}$, and $r_{c}$ is the exponential decreasing rate.

The quarantined rate $q$ is an increasing function with respect to time $t$ due to the strengthened contact tracing, which takes the following form $$q\left( t \right) = \left( {q_{0} - q_{b}} \right)e^{- r_{q}t} + q_{b},$$where $q_{b}$ is the quarantined rate at the initial time with $q\left( 0 \right) = q_{0}$, $q_{b}$ is the maximum quarantined rate under control measures with $\lim_{t\rightarrow\infty}q\left( t \right) = q_{b} > q_{0}$, and $r_{q}$ is the exponential increasing rate.

The quarantined rate of susceptible population with clinical fever symptoms $m\left( t \right)$ is a decreasing function with respect to time $t$, given by $$m\left( t \right) = \left( {m_{0} - m_{b}} \right)e^{- r_{m}t} + m_{b},$$where $m_{0}$ denotes the quarantined rate of susceptible population with fever symptoms at the initial time with $m\left( 0 \right) = m_{0}$, $m_{b}$ is the minimum quarantined rate of susceptible population with fever symptoms with $\lim_{t\rightarrow\infty}m\left( t \right) = m_{b} < m_{0}$, and $r_{m}$ is the exponential decreasing rate.

Due to the improvements of medical treatments and the strengthening of the production and supply of prevention and control products [@b15], disease-induced death rate $\alpha\left( t \right)$ decreases with respect to time $t$, and the recovery rate of confirmed individuals $\gamma_{H}\left( t \right)$ increases with respect to time $t$. Thus $\alpha\left( t \right)$ and $\gamma_{H}\left( t \right)$ take the following forms, $$\alpha\left( t \right) = \left( {\alpha_{0} - \alpha_{b}} \right)e^{- r_{\alpha}t} + \alpha_{b},\quad\quad\text{and}\quad\quad\gamma_{H}\left( t \right) = \left( {\gamma_{H0} - \gamma_{Hb}} \right)e^{- r_{\gamma}t} + \gamma_{Hb},$$where $\alpha_{0}$ is the disease-induced death rate at the initial time with $\alpha\left( 0 \right) = \alpha_{0}$, $\alpha_{b}$ is the minimum disease-induced death rate with $\lim_{t\rightarrow\infty}\alpha\left( t \right) = \alpha_{b} < \alpha_{0}$, and $r_{\alpha}$ is the exponential decreasing rate. $\gamma_{H0}$ denotes the recovery rate of confirmed individuals at the initial time with $\gamma_{H}\left( 0 \right) = \gamma_{H0}$, $\gamma_{Hb}$ denotes the maximum recovery rate of confirmed individuals with $\lim_{t\rightarrow\infty}\gamma_{H}\left( t \right) = \gamma_{Hb} > \gamma_{H0}$, and $r_{\gamma}$ denotes the exponential increasing rate.

Using the next generation matrix, we can define and calculate the effective reproduction number $R_{t}$ as follows: $$R_{t} = max\left\{ {R_{1}\left( t \right),R_{2}\left( t \right)} \right\},$$where $$R_{1}\left( t \right) = \frac{\rho\beta c\left( t \right)\left( 1 - q\left( t \right) \right)S_{t}}{\left( \alpha\left( t \right) + \delta_{I}\slash\left( {1 + \omega\left( t \right)S_{ft}} \right) \right)N} + \frac{\left( 1 - \rho \right)\beta_{A}c\left( t \right)S_{t}}{\gamma_{A}N},$$and $$R_{2}\left( t \right) = \frac{\beta_{f}c_{f}S_{ft}}{\left( \alpha\left( t \right) + \delta_{q}\slash\left( {1 + \omega\left( t \right)S_{ft}} \right) \right)}\quad\text{with}\quad S_{t} = S\left( t \right)\quad\text{and}\quad S_{ft} = S_{f}\left( t \right).$$Note that $R_{2}\left( t \right)$ represents the effective reproduction number of cross-infected individuals.

3. Main results {#sec3}
===============

3.1. Parameter estimation process {#sec3.1}
---------------------------------

In order to fit the model to the data, we firstly fix some parameters of our model from previous literature to reduce the complexity. In particular, the contact rate and the quarantined rate at the initial time are fixed as $c_{0} = 14.781$ [@b11] and $q_{0} = 1.0 \times 10^{- 4}$ [@b12], respectively. The incubation period is fixed as $5$ days [@b13], i.e. $\left. \sigma = 1\slash 5 \right.$, the releasing rate of quarantined susceptible individuals is fixed as $\left. \lambda = 1\slash 14 \right.$ [@b11], while the recovery rate of the asymptomatic infected individuals is fixed as $\gamma_{A} = 0.13978$ [@b11]. In addition, we fix the initial quarantined susceptible population, confirmed and hospitalized population, and recovered population as $7374$, $771$ and $34$ respectively according to the data information.

By simultaneously fitting the proposed model to the cumulative number of confirmed cases, cumulative number of death cases, cumulative number of cured cases and cumulative number of suspected cases, we first estimate the rest parameters and initial conditions using the least square method. The best fitting curves are marked as red in [Fig. 3](#fig3){ref-type="fig"} with the blue circles representing the data from January 23rd to March 29th 2020. The detailed estimated values of the parameters and initial conditions are listed in [Table 1](#tbl1){ref-type="table"}.

It is worth mentioning that we use four time series of data to fit the model, simultaneously, which can cross-validate the estimation results. Furthermore, based on the available information, the least squares method with a *priori* distribution for each parameter is used in this study. In another word, we implicitly utilize a penalized least square method to select reasonable parameter values falling in the ranges which were estimated in other published studies. Particularly, our estimated minimum contact rate with control strategies is 2.0 which is consistent with contact surveys in study [@b16], and the transition rate of quarantined exposed individuals to the quarantined infected class is estimated as $\sigma_{q} = 0.2$ being in line with the incubation period [@b13]. It was illustrated in [@b17] that it takes about 2 days from the start of sampling to the return of results, indicating that our estimation value of fast diagnose rate of infected individuals $\delta_{I} = 0.5$ is reasonable. Furthermore, the estimated initial number of detection kits per day $\left. 1\slash\omega_{0} = 2000 \right.$ is highly consistent with the news reported in the Beijing News [@b17].Fig. 3Best model fitting result. The red curves are the best fitting curves, and the blue circles denote the cumulatively confirmed cases, cumulatively death cases, cumulatively cured cases and cumulatively suspected cases.

Furthermore, we use the coefficient of determination ($R^{2}$) to estimate the goodness of fit for our model fitting results. Given a data set with $n$ observed value $y_{1},\ldots,y_{n}$. The corresponding estimated values from the model are defined as $f_{1},\ldots,f_{n}$ and $\overline{y} = \frac{1}{n}\sum_{i = 1}^{n}y_{i}$ is the average observed value, then the coefficient of determination value ($R_{2}$) can be defined as $R^{2} = 1 - \frac{SS_{res}}{SS_{tot}}$ with $SS_{res} = \sum_{i = 1}^{n}\left( {y_{i} - f_{i}} \right)^{2}$ denoting the sum of squares of residuals and $SS_{tot} = \sum_{i = 1}^{n}\left( {y_{i} - \overline{y}} \right)^{2}$ denoting the total sum of squares. Therefore, we obtain the coefficients of determination for the model fitting results in [Fig. 3](#fig3){ref-type="fig"}(A-D) being 0.9905, 0.988, 0.9884 and 0.9868, respectively. This indicates that the model fits the data very well.

3.2. Impacts of limited detection kits {#sec3.2}
--------------------------------------

Detection kits for COVID-19 were firstly introduced and used on January 16th 2020, but with very limited number. Since January 23rd 2020, detection kits were delivered to Hubei province from other provinces in China. Since it took time to increase the production of kits and improve the level of production technology, there was a serious shortage of detection kits during the initial stage of the COVID-19 epidemics. To examine the impacts of the limited detection kits on the COVID-19 epidemics in terms of the cumulative number of confirmed cases, the cumulative number of cross-infected cases and the infected population ($I\left( t \right)$), we vary the increasing rate of the available detection kits $r_{\omega}$ in [Fig. 4](#fig4){ref-type="fig"}. It follows from [Fig. 4](#fig4){ref-type="fig"} that reducing $r_{\omega}$ will significantly increase both the cumulative number of confirmed cases and cross-infected cases, and the infected population of $I\left( t \right)$ and daily cross-infected population at the peak time. Particularly, the cumulatively confirmed cases and cumulatively cross-infected cases will increase 3.5 times (about $2.084 \times 10^{5}$ cases) and 4.7 times (about $1.483 \times 10^{4}$ cases), respectively, if the exponential increasing rate $r_{\omega}$ decreases by $80$ percent. This means that deficiency and delay of detection cause more serious outbreaks. In another word, speeding up the production of detection kits and improve the detection capability play an important role in reducing the final size of infections.

When faced with limited detection kits supply, we show the impacts of public health interventions on the outbreak of COVID-19, as seen in [Table 2](#tbl2){ref-type="table"}. In particular, increasing $r_{c}$ or $r_{q}$ remarkably reduces the cumulative number of confirmed cases. Specifically, when $r_{\omega}$ is very small ($r_{\omega} = 0.1 \times r_{\omega}^{0}$), i.e. the testing kits production increases very slowly, then (1). If $r_{c}$ increases by $5$ times, the cumulative number of confirmed cases will decrease by 93.6%; (2). If $r_{q}$ increases by $5$ times, the cumulative number of confirmed cases will decrease by 78.7%. In addition, comparing the results in [Table 2](#tbl2){ref-type="table"}, we find that the impact of increasing $r_{c}$ or $r_{q}$ on mitigating the epidemics weakens as $r_{\omega}$ increases. This implies that rapid implementation of public health interventions, such as reducing contact rate and enhancing quarantined rate, is a good way to compensate the shortage of detection kits, and it is more indispensable for countries with severe limited resource of detection kits.Fig. 4The effects of varying the increasing rate of available detection kits $r_{\omega}$ on the COVID-19 epidemic in mainland China. $r_{\omega}^{0}$ denotes the estimated value of $r_{\omega}$.Table 2The impacts of public health interventions on the cumulative number of confirmed cases when faced with limited detection kits supply.Value of $r_{\omega}$Cumulative number of confirmed cases with varying $r_{c}$Cumulative number of confirmed cases with varying $r_{q}$$r_{c} = r_{c}^{0}$$r_{c} = 2 \ast r_{c}^{0}$$r_{c} = 5 \ast r_{c}^{0}$$r_{q} = r_{q}^{0}$$r_{q} = 2 \ast r_{q}^{0}$$r_{q} = 5 \ast r_{q}^{0}$$r_{\omega} = 0.1 \ast r_{\omega}^{0}$$9.564 \times 10^{5}$$1.859 \times 10^{5}$$6.087 \times 10^{4}$$9.564 \times 10^{5}$$3.981 \times 10^{5}$$2.035 \times 10^{5}$(−80.6%)(−93.6%)(−58.4%)(−78.7%)$r_{\omega} = 0.4 \ast r_{\omega}^{0}$$1.357 \times 10^{5}$$5.910 \times 10^{4}$$2.649 \times 10^{4}$$1.357 \times 10^{5}$$1.045 \times 10^{5}$$7.759 \times 10^{4}$(−56.4%)(−80.5%)(−23.0%)(−42.8%)$r_{\omega} = 0.7 \ast r_{\omega}^{0}$$9.510 \times 10^{4}$$4.539 \times 10^{4}$$2.223 \times 10^{4}$$9.510 \times 10^{4}$$7.685 \times 10^{4}$$6.003 \times 10^{4}$(−52.3%)(−76.6%)(−19.2%)(−36.9%)$r_{\omega} = r_{\omega}^{0}$$8.302 \times 10^{4}$$4.069 \times 10^{4}$$2.070 \times 10^{4}$$8.302 \times 10^{4}$$6.80 \times 10^{4}$$5.40 \times 10^{4}$(−51.0%)(−75.1%)(−18.1%)(−35.0%)[^1]

It is also interesting to observe from [Fig. 5](#fig5){ref-type="fig"}(A) that the estimated effective reproduction number (the blue curve) will first experience a short-period increasing before it decreases below the threshold $1$. However, we further observe that if we increase the rate of $r_{\omega}$ by $5$ times (the red curve in [Fig. 5](#fig5){ref-type="fig"}(A)), the effective reproduction number will decrease below the threshold $1$ directly. This indicates that due to the limited resource of the testing kits, the fast-increased infected population will result in more infections as they are not confirmed and hospitalized. And the situation will become worse if $r_{\omega}$ is smaller, shown in [Fig. 5](#fig5){ref-type="fig"}(A) as well. Furthermore, it follows from [Fig. 5](#fig5){ref-type="fig"}(B) and (C) that increasing $r_{c}$ or $r_{q}$ can avoid the magnification of the effective reproduction number and make the threshold value reduce to $1$ ahead of time, which implies that reducing the contact rate quickly and increasing the quarantined rate can effectively avert the short-term intensification of the outbreak caused by the limited detection kits.Fig. 5(A) Estimated effective reproduction number (blue curve) and the variation of the effective reproduction number by varying $r_{\omega}$; (B) The variation of the effective reproduction number by varying $r_{c}$; (C) The variation of the effective reproduction number by varying $r_{q}$. Here $r_{\omega}^{0}$ denotes the estimated value of the increasing rate of available detection kits $r_{\omega}$, $r_{c}^{0}$ denotes the estimated value of the decreasing rate of contact rate $r_{c}$, and $r_{q}^{0}$ denotes the estimated value of the increasing rate of quarantined rate $r_{q}$.

3.3. Benefits of getting vaccinated against influenza {#sec3.3}
-----------------------------------------------------

The COVID-19 outbreak in China coincided partially with flu season, and it was difficult to distinguish COVID-19 accurately and rapidly from influenza-like-illnesses. As a result, individuals with clinical fever symptoms required medical treatment in high risk settings of COVID-19, and the risk of cross-infection increased. Here we seek to use our transmission dynamics model to explore the impact of mass influenza vaccination prior to the onset of flu season on controlling the transmission of COVID-19.

Note that, in our model, we assumed that due to the influenza-like-illness (ILI), the susceptible individuals ($S$) can be quarantined at a rate of $m$ (move to $S_{f}$), which is proportion to the susceptible population. Further, we assume that the susceptible population is vaccinated against influenza with an effective vaccination coverage rate $Vr$. Thus, the vaccinated population will not be quarantined because of the clinical fever symptoms, consequently, the rate at which the susceptible population is quarantined due to the ILI becomes $\left( 1 - Vr \right) \ast m \ast S$. Based on the above assumptions, we evaluate the impact of the mass influenza vaccination on the transmission dynamics of COVID-19.

In [Fig. 6](#fig6){ref-type="fig"}, by changing the vaccination coverage rate of $Vr$ and fixing all the other parameters as the estimated baseline values, we examine the impact of vaccination against influenza on the COVID-19 epidemics in China in terms of the final size and the peak values. It follows from [Fig. 6](#fig6){ref-type="fig"} that increasing the vaccination coverage rate against influenza can remarkably reduce the cumulative number of COVID-19 confirmed cases and cross-infected cases, and also reduce the peak number of $I\left( t \right)$ and daily cross-infected population. In more detail, we find that by a vaccination coverage rate of 90%, the cumulative number of confirmed cases can reduce by 23.0% (about 19062 total cases), moreover, the cumulative number of cross-infected cases can reduce by 92.9% (about 3700 cases). This implies that mass influenza vaccination could contribute significantly to the control of the outbreak of COVID-19 and significantly reduce the risk of cross-infection.Fig. 6The impacts of getting vaccinated against influenza on the COVID-19 epidemic in mainland China. Here "Vr" represents the vaccination coverage rate against influenza.

In addition, in [Fig. 7](#fig7){ref-type="fig"} we illustrate the impact of getting vaccine against influenza on the reduction of the cumulative number of confirmed cases and cross-infected cases incorporating the effect of limited testing kits and public health interventions, that is, with different increasing rate of available detection kits $r_{\omega}$ or different decreasing rate of contact rate $r_{c}$. As shown in [Fig. 6](#fig6){ref-type="fig"}, vaccination against influenza could reduce the cumulative numbers of confirmed cases and cumulative cross-infected cases, hereafter referred as the reduced confirmed cases and reduced cross-infected cases, respectively. It follows from [Fig. 7](#fig7){ref-type="fig"}($A_{1}$) and ($A_{2}$) that getting vaccinated against influenza could significantly reduce the cumulative number of confirmed cases and cross-infected cases with respect to $r_{\omega}$. We give the specific reduction rate with respect to different $r_{\omega}$ and vaccination coverage rate in [Table 3](#tbl3){ref-type="table"}. Specifically, when the vaccination coverage rate was 90%, the cumulative number of confirmed cases and cross-infected cases could reduce by 51.5% and 91.4% with $r_{\omega} = 0.1 \times r_{\omega}^{0}$, respectively. We can further observe that the effects of getting vaccinated against influenza weakens as $r_{\omega}$ increases. It means that getting vaccinated against influenza could effectively control the outbreak of COVID-19. Moreover, mass influenza vaccination is more necessary when detection kits are severely limited and under seriously shortage of supply. In another words, mass influenza vaccination can be a much more effective control measure in mitigating the COVID-19 epidemics in the early stage with a rapid growth and the countries or areas with limited testing kits.Fig. 7The total reduction number of cumulatively confirmed cases and the reduction of cumulatively cross-infected cases by different vaccination coverage rate against influenza with respect to $r_{\omega}$ (A~1~ and A~2~) and $r_{c}$ (B~1~ and B~2~). Here "Vr" represents the vaccination coverage rate against influenza.

Similarly, [Fig. 7](#fig7){ref-type="fig"}($B_{1}$) and ($B_{2}$) illustrate the impact of getting vaccinated on reducing the cumulative number of confirmed cases and cross-infected cases with respect to $r_{c}$, and the detailed reduction rate with respect to different $r_{c}$ and vaccination coverage rate is given in [Table 4](#tbl4){ref-type="table"}. Specifically, for a 90% vaccination coverage rate, the cumulative number of confirmed cases could reduce by 30.8%, and the cumulative number of cross-infected cases could reduce by 92.0% with $r_{c} = 0.1 \times r_{c}^{0}$, showing that if the contact rate was not fast controlled and reduced, mass vaccination could effectively aid the containment of COVID-19 outbreak.Table 3The impacts of getting vaccinated against influenza on the cumulative number of confirmed cases and the cumulative number of cross-infected cases with respect to $r_{\omega}$.Vaccination coverage rateCumulative number of confirmed casesCumulative number of cross-infected cases$r_{\omega} = 0.1 \ast r_{\omega}^{0}$$r_{\omega} = 0.4 \ast r_{\omega}^{0}$$r_{\omega} = 0.7 \ast r_{\omega}^{0}$$r_{\omega} = 0.1 \ast r_{\omega}^{0}$$r_{\omega} = 0.4 \ast r_{\omega}^{0}$$r_{\omega} = 0.7 \ast r_{\omega}^{0}$0$9.564 \times 10^{5}$$1.357 \times 10^{5}$$9.510 \times 10^{4}$$3.295 \times 10^{4}$$7.427 \times 10^{3}$$4.681 \times 10^{3}$$30\text{\%}$$8.273 \times 10^{5}$$1.189 \times 10^{5}$$8.616 \times 10^{4}$$2.245 \times 10^{4}$$4.380 \times 10^{3}$$2.844 \times 10^{3}$(−13.5%)(−12.4%)(−9.4%)(−31.9%)(−41.0%)(−39.2%)$60\text{\%}$$6.684 \times 10^{5}$$1.017 \times 10^{5}$$7.735 \times 10^{4}$$1.226 \times 10^{4}$$2.035 \times 10^{3}$$1.395 \times 10^{3}$(−30.1%)(−25.1%)(−18.7%)(−62.8%)(−72.6%)(−70.2%)$90\text{\%}$$4.635 \times 10^{5}$$8.386 \times 10^{4}$$6.860 \times 10^{4}$$2.830 \times 10^{3}$410.8309.2(−51.5%)(−38.2%)(−27.9%)(−91.4%)(−94.5%)(−93.4%)[^2]Table 4The impacts of getting vaccinated against influenza on the cumulative number of confirmed cases and the cumulative number of cross-infected cases with respect to $r_{c}$.Vaccination coverage rateCumulative number of confirmed casesCumulative number of cross-infected cases$r_{c} = 0.1 \ast r_{c}^{0}$$r_{c} = 0.5 \ast r_{c}^{0}$$r_{c} = r_{c}^{0}$$r_{c} = 0.1 \ast r_{c}^{0}$$r_{c} = 0.5 \ast r_{c}^{0}$$r_{c} = r_{c}^{0}$0$7.907 \times 10^{5}$$1.798 \times 10^{5}$$8.302 \times 10^{4}$$2.013 \times 10^{4}$$8.363 \times 10^{3}$$3.983 \times 10^{3}$$30\text{\%}$$7.062 \times 10^{5}$$1.632 \times 10^{5}$$7.644 \times 10^{4}$$1.314 \times 10^{4}$$5.222 \times 10^{3}$$2.460 \times 10^{3}$(−10.7%)(−9.2%)(−7.9%)(−34.7%)(−37.6%)(−38.2%)$60\text{\%}$$6.249 \times 10^{5}$$1.472 \times 10^{5}$$7.010 \times 10^{4}$$6.927 \times 10^{3}$$2.641 \times 10^{3}$$1.235 \times 10^{3}$(−21.0%)(−18.1%)(−15.6%)(−65.6%)(−68.4%)(−69.0%)$90\text{\%}$$5.468 \times 10^{5}$$1.317 \times 10^{5}$$6.393 \times 10^{4}$$1.616 \times 10^{3}$601.2283.0(−30.8%)(−26.8%)(−23.0%)(−92.0%)(−92.8%)(−92.9%)[^3]

4. Discussions and conclusions {#sec4}
==============================

In the present mathematical modeling study, we have tested the hypothesis that a mass influenza vaccination campaign would have a positive effect on the management of people with non-specific symptoms and complaining of ILIs, potentially at risk of developing the COVID-19 (or other emerging respiratory infections) during their admission at the health-care setting. Our findings show that increasing influenza vaccination coverage rate to an optimal threshold would facilitate the efforts of containing the COVID-19 outbreak.

According to some researchers, the SARS-CoV-2 had already been circulating much earlier than late December 2019 but its correct identification was hindered by a considerable amount of people complaining of influenza-like-illness (ILI) symptoms. In the case of the implementation of a mass influenza vaccination campaign well before the onset of the influenza season, the exposure of emerging/re-emerging respiratory pathogens would be unmasked, facilitating their identification and the design of ad hoc public health interventions. This would significantly alleviate the pressure on health-care facilities, reducing the total number of people complaining of ILI symptoms, and decreasing the transmission probability of COVID-19 or other emerging infectious agents both among healthcare workers and, subsequently, among people under investigation for their disease.

Influenza generates a relevant burden worldwide, both in terms of healthcare resources consumption and socio-economic impact. Despite the existence of effective vaccines and their importance as cost-effective preventative tool, vaccination coverage rate still remains suboptimal. With respect to the general population, healthcare workers are at a higher risk of exposure to circulating respiratory pathogens, including influenza, potentially threatening their own health and compromising patients' safety. Influenza vaccine uptake is suboptimal also among other targeted categories, including the elderly and disabled people. An inadequate disease risk perception, a low health literacy, perception of the societal effects of vaccination and alleged side-effects are among the drivers of vaccine hesitancy.

Influenza vaccination would enable to better control and contain the spread of COVID-19 or other emerging/re-emerging pathogens, in case of coincidence of the outbreak with the influenza season. Mass influenza vaccination prior to the onset of the peak influenza season would significantly decrease the number of ILIs among the general population and specifically the elderly, with fewer persons with ILIs seeking for medical advice, particularly those in high-risk settings, with frailty, underlying co-morbidities or disabled. As such, this would minimize the probability of not quickly and accurately identifying circulating respiratory pathogens as well as the possibility of ongoing nosocomial transmission.

However, how to increase influenza vaccination coverage rate remains challenging. Mandatory policies for targeted categories are under debate in several countries. Also, in this study, we did not consider explicitly the efficacy of the influenza vaccine, and the vaccination coverage should be an effective vaccination rate. However, we believe that this study provided a fundamental framework for quantitatively evaluating the impact of vaccination against influenza on mitigating the COVID-19 epidemics. Public health decision- and policy-makers should adopt evidence-informed strategies to improve influenza vaccine uptake, given its impact on respiratory pandemic outbreaks coinciding with the peak influenza season and the shortage of medical personnel and equipment, including diagnostic tests.
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[^1]: Note that $r_{\omega}^{0}$, $r_{c}^{0}$ and $r_{q}^{0}$ are the estimated value of $r_{\omega}$, $r_{c}$ and $r_{q}$, respectively.

[^2]: Here $r_{\omega}^{0}$ is the estimated value of $r_{\omega}$.

[^3]: Here $r_{c}^{0}$ is the estimated value of $r_{c}$.
